Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Neurofilament light chain… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy

Artikel i vetenskaplig tidskrift
Författare C. Meregalli
G. Fumagalli
P. Alberti
A. Canta
V. A. Carozzi
A. Chiorazzi
L. Monza
E. Pozzi
Åsa P Sandelius
Kaj Blennow
Henrik Zetterberg
P. Marmiroli
G. Cavaletti
Publicerad i Experimental Neurology
Volym 307
Sidor 129-132
ISSN 0014-4886
Publiceringsår 2018
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 129-132
Språk en
Länkar dx.doi.org/10.1016/j.expneurol.2018...
Ämnesord Neurofilament light, Blood biomarker, Chemotherapy-induced peripheral neurotoxicity, Vincristine, Neurosciences & Neurology
Ämneskategorier Neurokemi

Sammanfattning

The objective of this study is to test the feasibility of using serum neurofilament light chain (NfL) as a disease biomarker in Chemotherapy Induced Peripheral Neuropathy (CIPN) since this easy accessible biological test may have a large impact on clinical management and safety of cancer patients. We performed this preclinical study using a well-characterized rat model based on repeated administration of the cytostatic drug vincristine (VCR, 0.2 mg/kg intravenously via the tail vein once/week for 4 times). Serial NfL serum concentration was measured using the in-house Simoa NfL assay and peripheral neuropathy onset was measured by sensory and motor nerve conduction studies. Serum NfL measure in untreated and VCR-treated rats demonstrated a steady, and significant increase during the course of VCR administration, with a final 4-fold increase with respect to controls (p < .001) when sign of axonopathy and loss of intraepidermal nerve fibers were clearly evident and verified by behavioral, neurophysiological and pathological examination. This simple monitoring approach based on serum NfL concentration measures may be easily translated to clinical practice and should be considered as a putative marker of CIPN severity in a typical oncology outpatient setting. Further studies are needed to validate its utility in cancer patients treated with different neurotoxic drugs.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?